×
About 19,588 results

ALLMedicine™ Parkinson Disease Center

Research & Reviews  9,553 results

Pioglitazone and statins lower incidence of Parkinson disease in patients with diabetes...
https://doi.org/10.1111/ene.14542
European Journal of Neurology; Chang YH, Yen SJ et. al.

Sep 24th, 2020 - The pharmacologic effects of pioglitazone on the incidence of Parkinson disease (PD) are not clear. No study has examined the interaction between pioglitazone and statin treatment on prevention of PD. This study analyzed the associations between p...

Upregulation of DJ-1 expression in melanoma regulates PTEN/AKT pathway for cell surviva...
https://doi.org/10.1007/s00403-020-02139-1
Archives of Dermatological Research; Lee YJ, Kim WI et. al.

Sep 22nd, 2020 - Cutaneous melanoma is known to be one of the most dangerous skin cancers because of its metastatic functions. Today, it is essential to investigate specific biomarkers for the target treatment in many diseases including cancers. DJ-1 protein, also...

Argentine tango in the care of Parkinson's disease: A systematic review and analysis of...
https://doi.org/10.1016/j.ctim.2020.102474
Complementary Therapies in Medicine; Berti A, Pini M et. al.

Sep 21st, 2020 - To analyse the content of the interventions reported in studies investigating the applicability and efficacy of Argentine tango in participants with Idiopathic Parkinson Disease. Independent reviewers searched databases (PubMed, CINAHL, EMBASE, Ps...

Clinical and Striatal Dopamine Transporter Predictors of Mild Behavioral Impairment in ...
https://doi.org/10.1097/RLU.0000000000003281
Clinical Nuclear Medicine; Yoo HS, Lee S et. al.

Sep 21st, 2020 - Neuropsychiatric symptoms are important and frequent nonmotor features in Parkinson disease (PD). We explored mild behavioral impairment (MBI) in drug-naive patients with PD and its clinical and dopamine transporter (DAT) correlates. We recruited ...

The experiences of carers looking after people with Parkinson's disease who exhibit imp...
https://doi.org/10.1111/jocn.15499
Journal of Clinical Nursing; McKeown E, Saleem T et. al.

Sep 21st, 2020 - Impulsive and compulsive behaviours (ICBs) are a serious complication in Parkinson disease (PD) strongly associated with dopamine replacement therapy used to treat patients. These behaviours comprise abnormal activities such as pathological gambli...

see more →

Guidelines  157 results

Complementary Health Approaches for People With Parkinson Disease.
https://doi.org/10.1016/j.apmr.2020.03.024
Archives of Physical Medicine and Rehabilitation; Moon S, Sarmento CVM et. al.

Jul 7th, 2020 - Complementary Health Approaches for People With Parkinson Disease.|2020|Moon S,Sarmento CVM,Colgrove Y,Liu W,|

Gocovri Clinical Data
https://www.gocovrihcp.com/clinical-data/
Gocovrihcp.com

May 27th, 2020 - The efficacy and safety of GOCOVRI® 274 mg were evaluated in two Phase 3, randomized, placebo-controlled trials

Pain and dyskinesia in Parkinson's disease may share common pathophysiological mechanisms – An fMRI study
https://www.jns-journal.com/article/S0022-510X(20)30242-2/pdf
Journal of Neurological Sciences;

May 26th, 2020 - Parkinson's disease (PD) patients develop levodopa induced dyskinesia with disease progression from sensitization of central pathways. Pain pathways are also impacted with suggestions dyskinetic patients may process pain differently.

White matter hyperintensities and risk of levodopa‐induced dyskinesia in Parkinson’s disease
https://onlinelibrary.wiley.com/doi/full/10.1002/acn3.50991
Annals of Clinical and Translational Neurology;

Feb 6th, 2020 - To investigate whether the burden of white matter hyperintensities (WMHs) is associated with the risk of developing levodopa‐induced dyskinesia (LID) in Parkinson’s disease (PD).

Blood Flow and Glucose Metabolism Dissociation in the Putamen Is Predictive of Levodopa Induced Dyskinesia in Parkinson's Disease Patients
https://www.frontiersin.org/articles/10.3389/fneur.2019.01217/full
Frontiers in Neurology;

Nov 20th, 2019 - The forefront treatment of Parkinson's disease (PD) is Levodopa. When patients are treated with Levodopa cerebral blood flow is increased while cerebral metabolic rate is decreased in key subcortical regions including the putamen. This phenomenon ...

see more →

Drugs  15 results see all →

Clinicaltrials.gov  9,595 results

Pioglitazone and statins lower incidence of Parkinson disease in patients with diabetes...
https://doi.org/10.1111/ene.14542
European Journal of Neurology; Chang YH, Yen SJ et. al.

Sep 24th, 2020 - The pharmacologic effects of pioglitazone on the incidence of Parkinson disease (PD) are not clear. No study has examined the interaction between pioglitazone and statin treatment on prevention of PD. This study analyzed the associations between p...

Upregulation of DJ-1 expression in melanoma regulates PTEN/AKT pathway for cell surviva...
https://doi.org/10.1007/s00403-020-02139-1
Archives of Dermatological Research; Lee YJ, Kim WI et. al.

Sep 22nd, 2020 - Cutaneous melanoma is known to be one of the most dangerous skin cancers because of its metastatic functions. Today, it is essential to investigate specific biomarkers for the target treatment in many diseases including cancers. DJ-1 protein, also...

Argentine tango in the care of Parkinson's disease: A systematic review and analysis of...
https://doi.org/10.1016/j.ctim.2020.102474
Complementary Therapies in Medicine; Berti A, Pini M et. al.

Sep 21st, 2020 - To analyse the content of the interventions reported in studies investigating the applicability and efficacy of Argentine tango in participants with Idiopathic Parkinson Disease. Independent reviewers searched databases (PubMed, CINAHL, EMBASE, Ps...

Clinical and Striatal Dopamine Transporter Predictors of Mild Behavioral Impairment in ...
https://doi.org/10.1097/RLU.0000000000003281
Clinical Nuclear Medicine; Yoo HS, Lee S et. al.

Sep 21st, 2020 - Neuropsychiatric symptoms are important and frequent nonmotor features in Parkinson disease (PD). We explored mild behavioral impairment (MBI) in drug-naive patients with PD and its clinical and dopamine transporter (DAT) correlates. We recruited ...

The experiences of carers looking after people with Parkinson's disease who exhibit imp...
https://doi.org/10.1111/jocn.15499
Journal of Clinical Nursing; McKeown E, Saleem T et. al.

Sep 21st, 2020 - Impulsive and compulsive behaviours (ICBs) are a serious complication in Parkinson disease (PD) strongly associated with dopamine replacement therapy used to treat patients. These behaviours comprise abnormal activities such as pathological gambli...

see more →

News  255 results

Gocovri Clinical Data
https://www.gocovrihcp.com/clinical-data/
Gocovrihcp.com

May 27th, 2020 - The efficacy and safety of GOCOVRI® 274 mg were evaluated in two Phase 3, randomized, placebo-controlled trials

Pain and dyskinesia in Parkinson's disease may share common pathophysiological mechanisms – An fMRI study
https://www.jns-journal.com/article/S0022-510X(20)30242-2/pdf
Journal of Neurological Sciences;

May 26th, 2020 - Parkinson's disease (PD) patients develop levodopa induced dyskinesia with disease progression from sensitization of central pathways. Pain pathways are also impacted with suggestions dyskinetic patients may process pain differently.

Peter Lewitt, MD, on surgical options for LID in patients with Parkinson disease
https://www.mdedge.com/neurology/article/220065/parkinsons-disease/peter-lewitt-md-surgical-options-lid-patients-parkinson?channel=269

Apr 1st, 2020 - Peter A. LeWitt, MD, is a Professor of Neurology at Wayne State University School of Medicine and Director of the Parkinson Disease and Movement Disorder Program at Henry Ford Hospital in West Bloomfield, Michigan.

Michael Martini on therapy options for patients with Parkinson disease and levodopa-induced dyskinesia
https://www.mdedge.com/neurology/article/220063/parkinsons-disease/michael-martini-therapy-options-patients-parkinson?channel=269

Apr 1st, 2020 - Michael Martini is a MD/PhD student at Icahn School of Medicine at Mount Sinai in New York. He recently coauthored the manuscript "Recent Advances in the Development of Experimental Therapeutics for Levodopa-Induced Dyskinesia.

White matter hyperintensities and risk of levodopa‐induced dyskinesia in Parkinson’s disease
https://onlinelibrary.wiley.com/doi/full/10.1002/acn3.50991
Annals of Clinical and Translational Neurology;

Feb 6th, 2020 - To investigate whether the burden of white matter hyperintensities (WMHs) is associated with the risk of developing levodopa‐induced dyskinesia (LID) in Parkinson’s disease (PD).

see more →

Patient Education  13 results see all →